Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity.

Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K.

Clin Cancer Res. 2020 Jan 13. pii: clincanres.1485.2019. doi: 10.1158/1078-0432.CCR-19-1485. [Epub ahead of print]

PMID:
31932492
2.

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.

Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, Dawson DW, Radu CG, Donahue TR.

Theranostics. 2020 Jan 1;10(2):829-840. doi: 10.7150/thno.40195. eCollection 2020.

3.

Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.

Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG.

Cell Chem Biol. 2020 Feb 20;27(2):197-205.e6. doi: 10.1016/j.chembiol.2019.10.012. Epub 2019 Nov 13.

PMID:
31734178
4.

18F-FAC PET visualizes brain-infiltrating leukocytes in a mouse model of multiple sclerosis.

Chen BY, Ghezzi C, Villegas B, Quon A, Radu CG, Witte ON, Clark PM.

J Nucl Med. 2019 Oct 25. pii: jnumed.119.229351. doi: 10.2967/jnumed.119.229351. [Epub ahead of print]

PMID:
31653711
5.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PMID:
31495780
6.

Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.

Plamthottam S, Sun D, Van Valkenburgh J, Valenzuela J, Ruehle B, Steele D, Poddar S, Marshalik M, Hernandez S, Radu CG, Zink JI.

J Biol Inorg Chem. 2019 Aug;24(5):621-632. doi: 10.1007/s00775-019-01675-0. Epub 2019 Jun 27.

PMID:
31250199
7.

Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion.

Elliott IA, Dann AM, Xu S, Kim SS, Abt ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, Cabebe AE, Wu N, Li L, Le TM, Radu CG, Donahue TR.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6842-6847. doi: 10.1073/pnas.1812410116. Epub 2019 Mar 20.

8.

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M.

EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z.

9.

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.

Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI.

Cancer Metab. 2018 Apr 17;6:4. doi: 10.1186/s40170-018-0177-4. eCollection 2018.

10.

Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP.

J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30.

11.

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG.

Nat Commun. 2017 Aug 14;8(1):241. doi: 10.1038/s41467-017-00221-3.

12.

Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1786-1792. doi: 10.2967/jnumed.117.193359. Epub 2017 May 25.

13.

Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.

Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K.

J Nucl Med. 2017 Mar;58(3):374-378. doi: 10.2967/jnumed.116.182394. Epub 2016 Nov 3.

14.

XRCC1 Arg194TRp and Arg399Gln Polymorphisms and Risk of Non-Hodgkin Lymphoma in a Romanian Population.

Bogliş A, Radu CG, Tripon F, Crauciuc AG, Demian S, Duicu C, Bănescu C.

Rev Med Chir Soc Med Nat Iasi. 2016 Jul-Sep;120(3):644-50.

PMID:
30148297
15.

Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma.

Laks DR, Ta L, Crisman TJ, Gao F, Coppola G, Radu CG, Nathanson DA, Kornblum HI.

Mol Cancer Ther. 2016 Jun;15(6):1271-8. doi: 10.1158/1535-7163.MCT-15-0982. Epub 2016 Mar 29.

16.

[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4027-32. doi: 10.1073/pnas.1524212113. Epub 2016 Mar 28.

17.

A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase.

Minkovsky A, Sahakyan A, Bonora G, Damoiseaux R, Dimitrova E, Rubbi L, Pellegrini M, Radu CG, Plath K.

Epigenetics Chromatin. 2015 Oct 13;8:42. doi: 10.1186/s13072-015-0034-4. eCollection 2015.

18.

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.

Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, Haupt S, Pochampally R, Boss GR, Romero DG, Radu CG, Martinez LA.

Nat Commun. 2015 Jun 12;6:7389. doi: 10.1038/ncomms8389.

19.

Targeted noninvasive imaging of the innate immune response.

McCracken MN, Radu CG.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):5868-9. doi: 10.1073/pnas.1505899112. Epub 2015 May 1. No abstract available.

20.

Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.

Nomme J, Li Z, Gipson RM, Wang J, Armijo AL, Le T, Poddar S, Smith T, Santarsiero BD, Nguyen HA, Czernin J, Alexandrova AN, Jung ME, Radu CG, Lavie A.

J Med Chem. 2014 Nov 26;57(22):9480-94. doi: 10.1021/jm501124j. Epub 2014 Nov 7.

21.

Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.

Bunimovich YL, Nair-Gill E, Riedinger M, McCracken MN, Cheng D, McLaughlin J, Radu CG, Witte ON.

PLoS One. 2014 Aug 7;9(8):e104125. doi: 10.1371/journal.pone.0104125. eCollection 2014.

22.

The role of the DNA damage response in zebrafish and cellular models of Diamond Blackfan anemia.

Danilova N, Bibikova E, Covey TM, Nathanson D, Dimitrova E, Konto Y, Lindgren A, Glader B, Radu CG, Sakamoto KM, Lin S.

Dis Model Mech. 2014 Jul;7(7):895-905. doi: 10.1242/dmm.015495. Epub 2014 May 8.

23.

INDs for PET molecular imaging probes-approach by an academic institution.

Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME.

Mol Imaging Biol. 2014 Aug;16(4):441-8. doi: 10.1007/s11307-014-0735-2.

24.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

25.

Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.

Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG.

J Exp Med. 2014 Mar 10;211(3):473-86. doi: 10.1084/jem.20131738. Epub 2014 Feb 24.

26.

Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.

Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG.

J Med Chem. 2013 Sep 12;56(17):6696-708. doi: 10.1021/jm400457y. Epub 2013 Aug 15.

27.

High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers.

Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R.

Appl Radiat Isot. 2013 Aug;78:88-101. doi: 10.1016/j.apradiso.2013.04.024. Epub 2013 Apr 25.

PMID:
23702794
28.

Using the BLT humanized mouse as a stem cell based gene therapy tumor model.

Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA.

J Vis Exp. 2012 Dec 18;(70):e4181. doi: 10.3791/4181.

29.

Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.

Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG.

J Exp Med. 2012 Nov 19;209(12):2215-28. doi: 10.1084/jem.20121061. Epub 2012 Nov 12.

30.

In vivo imaging of therapy-induced anti-cancer immune responses in humans.

Aarntzen EH, Srinivas M, Radu CG, Punt CJ, Boerman OC, Figdor CG, Oyen WJ, de Vries IJ.

Cell Mol Life Sci. 2013 Jul;70(13):2237-57. doi: 10.1007/s00018-012-1159-2. Epub 2012 Oct 5. Review.

31.

Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications.

Yaghoubi SS, Campbell DO, Radu CG, Czernin J.

Theranostics. 2012;2(4):374-91. doi: 10.7150/thno.3677. Epub 2012 Apr 10.

32.

Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.

Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG.

J Nucl Med. 2012 Feb;53(2):275-80. doi: 10.2967/jnumed.111.090407. Erratum in: J Nucl Med. 2012 Mar;53(3):507. J Nucl Med. 2015 Feb;56(2):329.

33.

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: 10.1073/pnas.1115050108. Epub 2011 Nov 28.

34.

Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.

Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG.

J Biol Chem. 2012 Jan 2;287(1):446-54. doi: 10.1074/jbc.M111.314666. Epub 2011 Nov 9.

35.

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.

Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR.

Nat Med. 2011 Jun;17(6):738-43. doi: 10.1038/nm.2375. Epub 2011 May 22.

36.

Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors.

Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T.

ChemMedChem. 2011 Apr 4;6(4):623-7. doi: 10.1002/cmdc.201000541. Epub 2011 Jan 24. No abstract available.

37.

Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.

Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):711-21. doi: 10.1007/s00259-010-1666-z. Epub 2010 Dec 3.

38.

PET imaging of the immune system: immune monitoring at the whole body level.

Singh AS, Radu CG, Ribas A.

Q J Nucl Med Mol Imaging. 2010 Jun;54(3):281-90. Review.

PMID:
20639814
39.

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. doi: 10.1073/pnas.1008300107. Epub 2010 Jul 12.

40.

Novel PET probes specific for deoxycytidine kinase.

Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG.

J Nucl Med. 2010 Jul;51(7):1092-8. doi: 10.2967/jnumed.109.073361. Epub 2010 Jun 16. Erratum in: J Nucl Med. 2015 Feb;56(2):329.

41.

Imaging adoptive cell transfer based cancer immunotherapy.

Rabinovich BA, Radu CG.

Curr Pharm Biotechnol. 2010 Sep 1;11(6):672-84. Review.

PMID:
20497110
42.

PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice.

Nair-Gill E, Wiltzius SM, Wei XX, Cheng D, Riedinger M, Radu CG, Witte ON.

J Clin Invest. 2010 Jun;120(6):2005-15. doi: 10.1172/JCI41250. Epub 2010 May 17. Erratum in: J Clin Invest. 2010 Jul 1;120(7):2641.

43.

Targeting leukemia stem cells.

Mikkola HK, Radu CG, Witte ON.

Nat Biotechnol. 2010 Mar;28(3):237-8. doi: 10.1038/nbt0310-237. No abstract available.

PMID:
20212485
44.

Requirement for deoxycytidine kinase in T and B lymphocyte development.

Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5551-6. doi: 10.1073/pnas.0913900107. Epub 2009 Dec 31.

45.

AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas.

Guo D, Cloughesy TF, Radu CG, Mischel PS.

Cell Cycle. 2010 Jan 15;9(2):211-2. Epub 2010 Jan 6. No abstract available.

46.

Visualizing cancer and immune cell function with metabolic positron emission tomography.

Laing RE, Nair-Gill E, Witte ON, Radu CG.

Curr Opin Genet Dev. 2010 Feb;20(1):100-5. doi: 10.1016/j.gde.2009.10.008. Review.

47.

Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner.

Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG, Witte ON, Khurana Hershey GK, Rothenberg ME, Zimmermann N.

Blood. 2009 Sep 24;114(13):2774-82. doi: 10.1182/blood-2009-05-220681. Epub 2009 Jul 29.

48.

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.

Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12932-7. doi: 10.1073/pnas.0906606106. Epub 2009 Jul 22.

49.

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR.

J Am Chem Soc. 2009 Jul 22;131(28):9695-703. doi: 10.1021/ja9006707.

50.

A supramolecular approach for preparation of size-controlled nanoparticles.

Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR.

Angew Chem Int Ed Engl. 2009;48(24):4344-8. doi: 10.1002/anie.200900063.

Supplemental Content

Support Center